|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.11.25 - 07:33
|
Corporate News: Evotec SE (EQS)
|
|
|
Evotec erhält Meilenstein-Zahlung von Bristol Myers Squibb nach Zulassung eines IND-Antrags in der strategischen Partnerschaft im Bereich Protein Degradation...
|
|
|
|
|
05.11.25 - 22:24
|
Redwire Corporation Reports Third Quarter 2025 Financial Results (Business Wire)
|
|
|
Revenues for the third quarter of 2025 increased by 50.7% year-over-year to $103.4 million
During the third quarter of 2025, we achieved a Gross Margin of 16.3% and an Adjusted Gross Margin1 of 27.1%
Year-over-year increase in Book-to-Bill2 ratio to 1.25 and Contracted Backlog2 to $355.6 million as of the third quarter of 2025
Awarded contract to develop and deliver Roll-Out Solar Arrays for Axiom Space's first commercial space station module
Uncrewed aerial system deliveries during the quarter included Stalker systems for the U.S. Army's Long Range Reconnaissance program and Penguin systems for the Ukrainian Armed Forces
Launched 14 PIL-BOXes to the ISS during the third quarter of 2025 with three different partners: Bristol Myers Squibb, Butler University, and Purdue University
JACKSONVILLE, Fla.--(BUSINESS WIRE)--$RDW--Redwire Corporation (NYSE:RDW, “Redwire” or the “Company”), a global leader in space and defense technology solutions, today announced results for its third quarter ended Septem...
|
|
|
05.11.25 - 20:51
|
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes (Business Wire)
|
|
|
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has priced a public offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of €5 billion (collectively, the “Notes”). The Notes will be issued by Bristol Myers Squibb's wholly-owned subsidiary, BMS Ireland Capital Funding Designated Activity Company, in five tranches: (i) €750,000,000 aggregate principal amount of 2.973% Notes due 2030, (ii) €1,150,000,000 aggregate principal amount of 3.363% Notes due 2033, (iii) €1,150,000,000 aggregate principal amount of 3.857% Notes due 2038, (iv) €750,000,000 aggregate principal amount of 4.289% Notes due 2045, and (v) €1,200,000,000 aggregate principal amount of 4.581% Notes due 2055. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Bristol-Myers Squibb Company. Bristol Myers Squibb expects that the closing of the Offering will occur on November 10, 2025, subject to the satisfactio...
|
|
|
|
|
|
|
|
|
03.11.25 - 13:24
|
Biontech erhöht Umsatzziel (Cash)
|
|
|
Pharma - Der Mainzer Biotechkonzern BioNTech hat dank einer milliardenschweren Zahlung seines Partners Bristol Myers Squibb seine Umsatzprognose für dieses Jahr deutlich angehoben....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
